Literature DB >> 8630735

A point mutation in HLA-A*0201 results in failure to bind the TAP complex and to present virus-derived peptides to CTL.

A L Peace-Brewer1, L G Tussey, M Matsui, G Li, D G Quinn, J A Frelinger.   

Abstract

Mutating the HLA-A*0201 heavy chain from threonine to lysine at position 134 (T134K) results in a molecule that presents exogenous peptide, but cannot present endogenously derived antigen. This is reflected in diminished cell surface expression and altered intracellular trafficking of T134K. The failure of T134K to present endogenous antigen can be overcome by using an ER targeting sequence, suggesting that the antigen presentation defect is restricted to TAP-dependent peptide loading. The ability of T134K to load peptide in a TAP-dependent manner is dramatically reduced compared with HLA-A*0201. By coimmunoprecipitation there is no detectable association of the T134K molecule with the TAP complex. Thus, T134K selectively affects TAP association and peptide loading, suggesting a requirement for the direct interaction of MHC class I heavy chain and the TAP complex for efficient presentation of endogenous antigen.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630735     DOI: 10.1016/s1074-7613(00)80416-1

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  31 in total

1.  Productive association between MHC class I and tapasin requires the tapasin transmembrane/cytosolic region and the tapasin C-terminal Ig-like domain.

Authors:  Laura C Simone; Corey J Georgesen; Peter D Simone; Xiaojian Wang; Joyce C Solheim
Journal:  Mol Immunol       Date:  2011-12-12       Impact factor: 4.407

2.  Tapasin discriminates peptide-human leukocyte antigen-A*02:01 complexes formed with natural ligands.

Authors:  Gustav Roder; Linda Geironson; Michael Rasmussen; Mikkel Harndahl; Søren Buus; Kajsa Paulsson
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

3.  Conformational flexibility of the MHC class I alpha1-alpha2 domain in peptide bound and free states: a molecular dynamics simulation study.

Authors:  Martin Zacharias; Sebastian Springer
Journal:  Biophys J       Date:  2004-10       Impact factor: 4.033

4.  Direct peptide-regulatable interactions between MHC class I molecules and tapasin.

Authors:  Syed Monem Rizvi; Malini Raghavan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

5.  Requirements for the selective degradation of endoplasmic reticulum-resident major histocompatibility complex class I proteins by the viral immune evasion molecule mK3.

Authors:  Xiaoli Wang; Rose Connors; Michael R Harris; Ted H Hansen; Lonnie Lybarger
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Adapter-mediated substrate selection for endoplasmic reticulum-associated degradation.

Authors:  Kathleen Corcoran; Xiaoli Wang; Lonnie Lybarger
Journal:  J Biol Chem       Date:  2009-04-14       Impact factor: 5.157

7.  Cloning and functional analyses of the mouse tapasin promoter.

Authors:  Felix Herrmann; John Trowsdale; Christoph Huber; Barbara Seliger
Journal:  Immunogenetics       Date:  2003-08-26       Impact factor: 2.846

8.  Interaction of TAPBPR, a tapasin homolog, with MHC-I molecules promotes peptide editing.

Authors:  Giora I Morozov; Huaying Zhao; Michael G Mage; Lisa F Boyd; Jiansheng Jiang; Michael A Dolan; Ramesh Venna; Michael A Norcross; Curtis P McMurtrey; William Hildebrand; Peter Schuck; Kannan Natarajan; David H Margulies
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-11       Impact factor: 11.205

Review 9.  Cellular and molecular basis of immunodeficiencies: their consequences for the development and induction of the immune response.

Authors:  J Sterzl
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

10.  Association of beta2-microglobulin with the alpha3 domain of H-2Db heavy chain.

Authors:  Mirjana Lilić; Zoran Popmihajlov; John J Monaco; Stanislav Vukmanović
Journal:  Immunogenetics       Date:  2004-01-20       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.